Bicara Therapeutics releases corporate deck highlighting ficerafusp alfa EGFR-TGF-β program in HPV-negative head and neck cancer

• Bicara highlighted ficerafusp alfa (FICERA), an EGFR-directed antibody fused to a TGF-β ligand trap, as its lead oncology asset.
• Pivotal FORTIFI-HN01 in 1L recurrent or metastatic HPV-negative HNSCC targeted substantial enrollment by year-end, interim topline in mid-2027.
• Phase 1b in 1L R/M HPV-negative HNSCC showed confirmed ORR 48%-57% across regimens; median PFS 6.9-12.7 months; median OS 21.3 months at 1500mg QW.
• Cash, cash equivalents, marketable securities totaled USD 497.3 million as of June 30, 2026; runway projected into 1H 2029.
• Development plan included FORTIFI-FLEX alternate dosing study; additional signal-seeking in EGFR x TGF-β biology tumors such as cSCC, anal canal cancer, mCRC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.